Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.